Transcranial Magnetic Stimulation in Misophonia
ConditionMisophonia
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-55
SponsorIcahn School of Medicine at Mount Sinai
About this trial
The purpose of the project is to assess the efficacy of parietal transcranial magnetic stimulation in misophonia. N=60 participants will undergo two transcranial magnetic stimulation sessions: one inhibitory and another excitatory. During both sessions, the parietal region will be stimulated. Participants will perform computerized tasks immediately before and after the stimulation, while EEG, heart rate, and skin temperature will be recorded. These recordings will be used to assess if TMS can be used to improve tolerance to misophonia triggers.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Hypersensitive to presence of a specific sound, which may be accompanied by irritation, anger/outbursts, or fear.
Must be between the ages of 18 - 55.
Must be fluent in English since the study's instructions, surveys, and tasks will be in English.
Disqualifiers
Epilepsy or previous episode of convulsion or seizure.
Previous episode of fainting spell or syncope.
Head trauma.
Hearing problems.
Trial design
Design model
Crossover
Treatments tested in this trial
Transcranial Magnetic Stimulation (TMS)
Other interventionTranscranial Magnetic Stimulation (TMS) is an FDA-approved non-invasive brain stimulation technology. It is currently used for treating depression. Applications to other disorders such as OCD and anxiety using TMS are currently under investigation. TMS will be administered for 25 minutes.
Treatment groups
60 Participants
are divided into 2 treatment groupsGroup A: Inhibitory-Excitatory (IE) then Excitatory-Inhibitory (EI)Active comparator 1 intervention
Group B: Excitatory-Inhibitory (EI) then Inhibitory-Excitatory (IE)Active comparator 1 intervention
Trial outcomes
Primary outcomes
1
Unpleasantness Rating Scale
Participants will be presented with a slider with extremes labelled as extremely unpleasant and extremely pleasant. Ratings will be provided for audio clips and visual cues. Full scale from 0-100, higher score indicates more unpleasantness
Time frame
after each session, 72 hours apart (each session is 2 hours)Secondary outcomes
1
Heart Rate
The heart rate (number of beats per minute) will be measured using a wristwatch worn by the participant.
Time frame
after each session, 72 hours apart (each session is 2 hours)2
Skin Conductance Response
Skin conductance, a measure capturing the amount of sweat, will be measured using a wristwatch worn by the participant.
Time frame
after each session, 72 hours apart (each session is 2 hours)3
EEG P1-N1-P2 Complex Peak Amplitude
Amplitude (microvolts) of P1, N1, and P2 peaks measured in the parietal region
Time frame
after each session, 72 hours apart (each session is 2 hours)4
EEG P1-N1-P2 Complex Peak Latency
Latency (milliseconds) of P1, N1, and P2 peaks measured in the parietal region
Time frame
after each session, 72 hours apart (each session is 2 hours)Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov